Allarity Therapeutics Inc
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib… Read more
Allarity Therapeutics Inc (ALLR) - Total Liabilities
Latest total liabilities as of September 2025: $8.79 Million USD
Based on the latest financial reports, Allarity Therapeutics Inc (ALLR) has total liabilities worth $8.79 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Allarity Therapeutics Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how Allarity Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Allarity Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Allarity Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Acer Gadget Inc
TW:2432
|
Taiwan | NT$746.88 Million |
|
Anthem Biosciences Ltd
NSE:ANTHEM
|
India | ₹5.32 Billion |
|
Pasupati Acrylon Limited
NSE:PASUPTAC
|
India | ₹2.63 Billion |
|
FKS Food Sejahtera Tbk PT
JK:AISA
|
Indonesia | Rp942.71 Billion |
|
Manba Finance Ltd
NSE:MANBA
|
India | ₹14.99 Billion |
|
Taiwan Auto-Design Co.
TWO:6791
|
Taiwan | NT$274.25 Million |
|
Selva Gida Sanayi AS
IS:SELVA
|
Turkey | TL1.82 Billion |
|
Viceroy Hotels Limited
NSE:VHLTD
|
India | ₹661.04 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Allarity Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Allarity Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Allarity Therapeutics Inc (2013–2024)
The table below shows the annual total liabilities of Allarity Therapeutics Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $10.84 Million | -25.83% |
| 2023-12-31 | $14.61 Million | +15.48% |
| 2022-12-31 | $12.65 Million | -58.98% |
| 2021-12-31 | $30.85 Million | +370.83% |
| 2020-12-31 | $6.55 Million | -38.79% |
| 2019-12-31 | $10.70 Million | +0.17% |
| 2018-12-31 | $10.69 Million | +529.09% |
| 2017-12-31 | $1.70 Million | +27.11% |
| 2016-12-31 | $1.34 Million | +157.91% |
| 2015-12-31 | $518.15K | +3489.03% |
| 2014-12-31 | $14.44K | +15.01% |
| 2013-12-31 | $12.55K | -- |